179 related articles for article (PubMed ID: 16167521)
1. Glucan-associated protein modulations and ultrastructural changes of the cell wall in Candida albicans treated with micafungin, a water-soluble, lipopeptide antimycotic.
Angiolella L; Maras B; Stringaro AR; Arancia G; Mondello F; Girolamo A; Palamara AT; Cassone A
J Chemother; 2005 Aug; 17(4):409-16. PubMed ID: 16167521
[TBL] [Abstract][Full Text] [Related]
2. The lipopeptide antimycotic, cilofungin modulates the incorporation of glucan-associated proteins into the cell wall of Candida albicans.
Angiolella L; Simonetti N; Cassone A
J Antimicrob Chemother; 1994 Jun; 33(6):1137-46. PubMed ID: 7928807
[TBL] [Abstract][Full Text] [Related]
3. Morphological changes of Candida albicans induced by micafungin (FK463), a water-soluble echinocandin-like lipopeptide.
Nishiyama Y; Uchida K; Yamaguchi H
J Electron Microsc (Tokyo); 2002; 51(4):247-55. PubMed ID: 12227555
[TBL] [Abstract][Full Text] [Related]
4. Identification of a glucan-associated enolase as a main cell wall protein of Candida albicans and an indirect target of lipopeptide antimycotics.
Angiolella L; Facchin M; Stringaro A; Maras B; Simonetti N; Cassone A
J Infect Dis; 1996 Mar; 173(3):684-90. PubMed ID: 8627033
[TBL] [Abstract][Full Text] [Related]
5. The activity of cilofungin on the incorporation of glucan associated proteins into hyphal cells of Candida albicans.
Angiolella L; Facchin M; Simonetti N; Cassone A
J Chemother; 1995 Apr; 7(2):83-9. PubMed ID: 7666125
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of FK463, a (1,3)-beta-D-glucan synthase inhibitor, in disseminated azole-resistant candida albicans infection in mice.
Maesaki S; Hossain MA; Miyazaki Y; Tomono K; Tashiro T; Kohno S
Antimicrob Agents Chemother; 2000 Jun; 44(6):1728-30. PubMed ID: 10817741
[TBL] [Abstract][Full Text] [Related]
7. Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin.
Stevens DA; Ichinomiya M; Koshi Y; Horiuchi H
Antimicrob Agents Chemother; 2006 Sep; 50(9):3160-1. PubMed ID: 16940118
[TBL] [Abstract][Full Text] [Related]
8. Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro.
Jacobsen MD; Whyte JA; Odds FC
Antimicrob Agents Chemother; 2007 May; 51(5):1882-4. PubMed ID: 17307974
[TBL] [Abstract][Full Text] [Related]
9. Nanoscopic cell-wall architecture of an immunogenic ligand in Candida albicans during antifungal drug treatment.
Lin J; Wester MJ; Graus MS; Lidke KA; Neumann AK
Mol Biol Cell; 2016 Mar; 27(6):1002-14. PubMed ID: 26792838
[TBL] [Abstract][Full Text] [Related]
10. The efficiency of the benzothiazole APB, the echinocandin micafungin, and amphotericin B in fluconazole-resistant Candida albicans and Candida dubliniensis.
Melkusová S; Bujdáková H; Volleková A; Myoken Y; Mikami Y
Pharmazie; 2004 Jul; 59(7):573-4. PubMed ID: 15296100
[TBL] [Abstract][Full Text] [Related]
11. Glucan synthesis and its inhibition by cilofungin in susceptible and resistant strains of Candida albicans.
Angiolella L; Bromuro C; Simonetti N; Cassone A
J Med Vet Mycol; 1992; 30(5):369-76. PubMed ID: 1469538
[TBL] [Abstract][Full Text] [Related]
12. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.
Messer SA; Diekema DJ; Boyken L; Tendolkar S; Hollis RJ; Pfaller MA
J Clin Microbiol; 2006 Feb; 44(2):324-6. PubMed ID: 16455878
[TBL] [Abstract][Full Text] [Related]
13. The cell wall protein Rhd3/Pga29 is over-expressed in Candida albicans upon micafungin treatment.
Vavala E; Mignogna G; Spano F; Stringaro A; Colone M; Sanguinetti M; Maras B; Angiolella L
J Chemother; 2013 Dec; 25(6):332-40. PubMed ID: 24090751
[TBL] [Abstract][Full Text] [Related]
14. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi.
Tawara S; Ikeda F; Maki K; Morishita Y; Otomo K; Teratani N; Goto T; Tomishima M; Ohki H; Yamada A; Kawabata K; Takasugi H; Sakane K; Tanaka H; Matsumoto F; Kuwahara S
Antimicrob Agents Chemother; 2000 Jan; 44(1):57-62. PubMed ID: 10602723
[TBL] [Abstract][Full Text] [Related]
15. Deletions of the endocytic components VPS28 and VPS32 in Candida albicans lead to echinocandin and azole hypersensitivity.
Cornet M; Gaillardin C; Richard ML
Antimicrob Agents Chemother; 2006 Oct; 50(10):3492-5. PubMed ID: 17005841
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of disc diffusion and microdilution methods in susceptibility testing of micafungin against Candida species.
Ramírez M; Serrano MC; Castro C; López E; Almeida C; Fernández A; Romero A; Martín-Mazuelos E
J Antimicrob Chemother; 2006 Oct; 58(4):861-3. PubMed ID: 16916868
[TBL] [Abstract][Full Text] [Related]
17. Localisation of Bgl2p upon antifungal drug treatment in Candida albicans.
Angiolella L; Vitali A; Stringaro A; Mignogna G; Maras B; Bonito M; Colone M; Palamara AT; Cassone A
Int J Antimicrob Agents; 2009 Feb; 33(2):143-8. PubMed ID: 19013773
[TBL] [Abstract][Full Text] [Related]
18. Effect of Micafungin (FK463) on Candida albicans adherence to epithelial cells.
Borg-von Zepelin M; Zaschke K; Gross U; Monod M; Müller FM
Chemotherapy; 2002 Jul; 48(3):148-53. PubMed ID: 12138332
[TBL] [Abstract][Full Text] [Related]
19. The echinocandins.
Cappelletty D; Eiselstein-McKitrick K
Pharmacotherapy; 2007 Mar; 27(3):369-88. PubMed ID: 17316149
[TBL] [Abstract][Full Text] [Related]
20. Micafungin Enhances the Human Macrophage Response to Candida albicans through β-Glucan Exposure.
Guirao-Abad JP; Sánchez-Fresneda R; Machado F; Argüelles JC; Martínez-Esparza M
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29483123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
